Indeed, COX-2 inhibitors combined with chemotherapy could enhance the antitumor activity of chemotherapy and inhibit the growth of lung cancer cells.44 Additionally, a phase I clinical trial has indicated that the celecoxib plus erlotinib combination treatment might improve tumor response in patients with NSCLC harboring EGFR gene mutations. The gene discussed is PTGS2; the disease is lung carcinoma.